Evidence map›Paper›PMID 41550650›Full record

ArticlePharmaceutical science advances2025

GLDC interacts with VPS34 to inhibit tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma.

Zan Song, Hao Dong, Kailing Zhang, Bingke Qiao, Leilei Li, Zhicheng Zhang, Zhili Fan, Jing Li, Yu Li, Mengfei Liu and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Zan SongInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Hao DongInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Kailing ZhangInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Bingke QiaoInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Leilei LiInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Zhicheng ZhangInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Zhili FanInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Jing LiInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Yu LiInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Mengfei LiuInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Ying LiuInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Xinyu GuInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Tao ZhangInstitute of Immunopharmaceutical Sciences, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancer with high mortality and limited therapeutic strategy. Glycine decarboxylase (GLDC) is the key limiting enzyme in glycine breakdown metabolism and acts as oncogene or tumor suppressor to impact tumor onset and progression in a context dependent manner. However, the underlying mechanism of GLDC on autophagy and progression is largely unexplored in HCC. Here, we showed that GLDC overexpression inhibited cell proliferation, cell migration and promoted cell senescence and autophagy in HCC. Intriguingly, induced GLDC remarkably attenuated epithelial-mesenchymal transition (EMT) progress and tumor growth

Indexed as

AcetylationEpithelial-mesenchymal transitionGLDCHCCVPS34

Identifiers

PMID41550650
PMCPMC12709974

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.